News

Ahead of World Cancer Day, we highlight the impact My Cancer Navigator has had in the last five years. Our free information service has been a pillar of support for cancer patients globally.

The Anticancer Fund is excited to announce a groundbreaking collaboration aimed at advancing the field of rare cancer research, the ATTRACT-initiative. In a pioneering effort, five anti-cancer charities will dedicate 21 million euros to accelerate drug development for rare cancers through cross-border clinical academic research.

My Cancer Navigator takes center stage in a podcast produced by Delphine Rémy, renowned for her work on ‘Naître princesse, devenir guerrière’. The podcast delves into the core features and benefits of our information service for cancer patients. Listeners will hear from Gilles Van der Spek, who candidly shares his journey and highlights the impact My Cancer Navigator has had on his experience.

Patients with Acute Myeloid Leukemia (AML) have very few treatment options when the initial chemotherapy has failed. This is particularly true for patients over 60, or with co-morbidities, who are not eligible for stem cell transplantation. On average, they will survive only a few months.

The results of the AML-ViVA trial show that low dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients who do not respond to initial chemotherapy.

A Cambridge-led trial testing a potential new treatment combination for post-menopausal women with hormone driven breast cancer reports positive findings at the international San Antonio Breast Cancer Symposium.

The results show that either a high or low dose of megestrol when given with the standard hormone therapy, letrozole, could be more effective in stopping tumour growth than letrozole alone.

The Anticancer Fund aims to intensify its commitment to helping patients confronted with pancreatic cancer and finding solutions for treatment. As November marks Pancreatic Cancer Awareness Month, we underscore the urgent need for dedicated research during a meeting of the European REMEDi4ALL consortium.